Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04089865 · ClinicalTrials.gov registry record · Phase 4
Oral Versus Intravenous Tranexamic Acid
A Phase 4 study of Blood Loss and Blood Transfusion, sponsored by Hospital for Special Surgery, New York.
- Completed
- Registry status
- Phase 4
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT04089865 is a Phase 4 study of Blood Loss and Blood Transfusion that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 400 participants, above the 131-participant average among 8 other Blood Loss trials with a reported enrollment target (205% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04089865, a Phase 4 study of Blood Loss and Blood Transfusion, has completed, sponsored by Hospital for Special Surgery, New York.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this randomized clinical control trial is to determine whether oral TXA dosing in THA/TKA result in more blood loss and more transfusions compared to IV TXA dosing in patients undergoing THA/TKA under neuraxial anesthesia. The main questions it aims to answer are: Does oral TXA dosing in THA/TKA result in more blood loss compared to IV TXA dosing? Does oral TXA dosing in THA/TKA result in more transfusions compared to IV TXA dosing? Participants will be randomly assigned to either get the Oral TXA (1950mg) or the IV TXA (1g) on their day of surgery. Researchers will compare these groups to see if any differences emerged. 200 THA patients (100 Oral, 100 IV), 200 TKA patients (100 oral, 100 IV).
Conditions Studied
Interventions
- DRUG Tranexamic Acid
Study Locations (1)
New York
- Hospital for Special Surgery - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2019-09-17 |
| Est. Completion | 2021-11-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04089865
The ClinicalTrials.gov registry entry for NCT04089865 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 131-participant average among 8 other Blood Loss trials with a reported enrollment target (205% higher). The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Blood Loss appearing as the primary indexed condition, and to 1 intervention - of which Tranexamic Acid is the first listed.
NCT04089865 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04089865 about?
NCT04089865 is a clinical study titled "Oral Versus Intravenous Tranexamic Acid". The goal of this randomized clinical control trial is to determine whether oral TXA dosing in THA/TKA result in more blood loss and more transfusions compared to IV TXA dosing in patients undergoing THA/TKA under neuraxial anesthesia. The main questions it aims to answer are: Does oral TXA dosing i...
What is the current status of trial NCT04089865?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 400 participants. The study started on 2019-09-17. Estimated completion is 2021-11-10.
What conditions does trial NCT04089865 study?
This clinical trial studies the following conditions: Blood Loss, Blood Transfusion.
What interventions are being tested in trial NCT04089865?
The interventions under investigation include: Tranexamic Acid (DRUG).
Who is sponsoring clinical trial NCT04089865?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04089865 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blood Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes
RECRUITING · Phase 4
-
Extended Postoperative Oral Tranexamic Acid in Knee Replacement
ACTIVE NOT RECRUITING · Phase 4
-
Oxytocin Pharmacokinetics and Pharmacodynamics
RECRUITING · Phase 2
-
LBNP Tolerance With Skin Warming After Exercise Cold Stress
ACTIVE NOT RECRUITING · NA
-
Effect of Prophylactic Tranexamic Acid on Bleeding Outcomes for Dilation and Evacuation
COMPLETED · Phase 2
-
Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.